Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Synthesis, antiviral activity and pharmacokinetics of P1/P1' substituted 3-aminoindazole cyclic urea HIV protease inhibitors.
Kaltenbach RF 3rd, Patel M, Waltermire RE, Harris GD, Stone BR, Klabe RM, Garber S, Bacheler LT, Cordova BC, Logue K, Wright MR, Erickson-Viitanen S, Trainor GL. Kaltenbach RF 3rd, et al. Among authors: logue k. Bioorg Med Chem Lett. 2003 Feb 24;13(4):605-8. doi: 10.1016/s0960-894x(02)01064-8. Bioorg Med Chem Lett. 2003. PMID: 12639540
Improved P1/P1' substituents for cyclic urea based HIV-1 protease inhibitors: synthesis, structure-activity relationship, and X-ray crystal structure analysis.
Nugiel DA, Jacobs K, Cornelius L, Chang CH, Jadhav PK, Holler ER, Klabe RM, Bacheler LT, Cordova B, Garber S, Reid C, Logue KA, Gorey-Feret LJ, Lam GN, Erickson-Viitanen S, Seitz SP. Nugiel DA, et al. Among authors: logue ka. J Med Chem. 1997 May 9;40(10):1465-74. doi: 10.1021/jm960839i. J Med Chem. 1997. PMID: 9154969
DPC 681 and DPC 684: potent, selective inhibitors of human immunodeficiency virus protease active against clinically relevant mutant variants.
Kaltenbach RF 3rd, Trainor G, Getman D, Harris G, Garber S, Cordova B, Bacheler L, Jeffrey S, Logue K, Cawood P, Klabe R, Diamond S, Davies M, Saye J, Jona J, Erickson-Viitanen S. Kaltenbach RF 3rd, et al. Among authors: logue k. Antimicrob Agents Chemother. 2001 Nov;45(11):3021-8. doi: 10.1128/AAC.45.11.3021-3028.2001. Antimicrob Agents Chemother. 2001. PMID: 11600351 Free PMC article.
Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
Bacheler L, Jeffrey S, Hanna G, D'Aquila R, Wallace L, Logue K, Cordova B, Hertogs K, Larder B, Buckery R, Baker D, Gallagher K, Scarnati H, Tritch R, Rizzo C. Bacheler L, et al. Among authors: logue k. J Virol. 2001 Jun;75(11):4999-5008. doi: 10.1128/JVI.75.11.4999-5008.2001. J Virol. 2001. PMID: 11333879 Free PMC article.
Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV from the Canadian cohort of the observational BICSTaR study.
Wong A, Brunetta J, De Wet J, Logue K, Loemba H, Saifi T, Mumm D, Marongiu A, Harrison R, Thorpe D, Trottier B. Wong A, et al. Among authors: logue k. Medicine (Baltimore). 2024 Apr 19;103(16):e37785. doi: 10.1097/MD.0000000000037785. Medicine (Baltimore). 2024. PMID: 38640301 Free PMC article.
43 results